Osgood Schlatter Companies
Osgood-Schlatter disease is a medical condition that primarily affects adolescents, causing inflammation and pain below the knee joint where the patellar tendon attaches to the shinbone.
Osgood-Schlatter disease is a medical condition that primarily affects adolescents, causing inflammation and pain below the knee joint where the patellar tendon attaches to the shinbone.
Latest Osgood-Schlatter Companies Update
Nov 2023: Due to its involvement in a "domestic antitrust cartel" in the United States, the American arm of the massive generic medication manufacturer Teva Pharmaceuticals faces a contract prohibition with the Canadian government that won't expire until the spring of 2025. In October, Teva Pharmaceuticals USA agreed to pay a US$225 million criminal penalty for participating in price-fixing conspiracies involving three pharmaceuticals in the United States. As a result, the company was placed on the Canadian government's list of suppliers ineligible or suspended. The company's local subsidiary, Teva Canada, is exempt from the prohibition, which is only set to expire in April 2025 but may be prolonged. According to a corporate regulatory attorney, it essentially amounts to a reprimand. According to the government's contract database, Teva Canada is currently involved in at least two active contracts. One is valued at more than $3 million and is for "multi-source pharmaceuticals," while the other was granted in July and is for generic medications valued at more than $700,000.
The Osgood-Schlatter market is expected to reach USD 3,554.27 Million by 2030, and the market is projected to grow at a CAGR of ~ 4.10% during the forecast period 2022-2030.Osgood–Schlatter disease (OSD), is the inflammation of area below the knee characterized by a painful bump just below the knee which worsens with activity. OSD typically affects growing adolescents during puberty and is common in those participating in sports and other physical activities. OSD causes a painful lump below the kneecap, resulting in swelling and tenderness affecting the knee. Risk factors include high intensity sports such as running or jumping.
OSD generally resolves with time especially with rest. OSD affects 4% of people at least once in their lifetime and is more common in males between the ages of 10 and 15. The male to female ratio is approximately 5:1.
The symptoms of OSD includes knee pain, swelling, tenderness, increased warmth under the knee and others. In extreme cases OSD may result in fracture.
The market drivers for Osgood-Schlatter market are rise in population, increasing awareness and screening, development of healthcare and orthopaedic centres, rise in sports culture, growth of physiotherapy and advancements in drugs and surgery etc. The market restraints are the complications of treatment such as pain, bleeding, high cost of treatment, competition from alternative treatment and self-correcting nature of the disease etc.
Research Methodology
Sources: Mayo Clinic, Healthline Media, MRFR Analysis
Intended Audience
Segments
The Osgood-Schlatter market has been segmented on the basis of diagnosis, treatment and end user.
Based on the diagnosis, the Osgood-Schlatter market has been segmented as physical examination, ultrasonography, X-ray, combination, and other.
Based on the treatment, the Osgood-Schlatter market has been segmented as non-steroidal anti-inflammatory drugs, physical therapy, knee braces and supports, surgery, and others.
Based on the end user, the Osgood-Schlatter market has been segmented as hospitals & clinics, academic and research, and others.
Regional Analysis
The Americas account for a significant market share owing to high expenditure on the health care. Additionally, the fastest uptake of new healthcare products in the US drives the Osgood-Schlatter market. Furthermore, concentration of the major healthcare companies and hospitals in the developed countries of this region coupled with large insurance penetration is adding fuel to the market growth. Moreover, the US expend high amount on its healthcare, which accounts for 16% of total GDP, which also increases the sale in Osgood-Schlatter market.
Europe is the second largest market in the world due to high income and strong healthcare penetration. The European market growth is led by countries such as Germany and France. The UK is expected to be the fastest growing market over the assessment period. The strong pharmaceutical industry in Germany is a strong driver behind the dominance of this country in Europe.
The large sporting culture and popularity of sports and media influence in the developed regions is expected to drive the future market.
Asia Pacific region is expected to grow rapidly; China and India are likely to lead this market due to fast growing healthcare sector and large unmet needs over the forecast period. South East Asian countries such as China, India, and Malaysia are projected to contribute highly to the market growth. The growing penetration of healthcare insurance in the Asia Pacific region is expected to drive the future Osgood-Schlatter market in the region.
Gulf nations such as Saudi Arabia and the UAE are estimated to drive the Middle East & African market. Other Middle East nations to watch out for are Kuwait, Jordan, Egypt, and Iran. The African region is expected to witness a moderate growth owing to poor economic and political conditions, and poor healthcare development.
Key Players in the Global Osgood-Schlatter Market
Some of the key players profiled in the Osgood-Schlatter market report are DJO Global, Inc., Teva Pharmaceutical Industries Ltd., Breg, Inc., Bayer HealthCare Pharmaceuticals LLC, Ossur HF, Daiichi Sankyo Company, Limited, Pfizer, Inc., Novartis AG, and others.
Osgood Schlatter Market Highlights:
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)